Matt Miksic
Stock Analyst at Barclays
Total Price Targets
27
Stocks Covered
18
Sectors
Healthcare
Most Recent
Apr 15, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Matt Miksic
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $255.00 | $227.97 | +11.9% | 3 | Apr 15, 2026 |
| TNDM | Tandem Diabetes Care, Inc. | $56.00 | $19.34 | +189.6% | 2 | Feb 23, 2026 |
| MDT | Medtronic plc | $118.00 | $80.42 | +46.7% | 2 | Feb 18, 2026 |
| ZBH | Zimmer Biomet Holdings, Inc. | $100.00 | $83.24 | +20.1% | 1 | Feb 12, 2026 |
| BDX | Becton, Dickinson and Company | $202.00 | $149.07 | +35.5% | 2 | Feb 10, 2026 |
| BAX | Baxter International Inc. | $30.00 | $17.25 | +73.9% | 2 | Jan 9, 2026 |
| COO | The Cooper Companies, Inc. | $91.00 | $62.51 | +45.6% | 2 | Dec 8, 2025 |
| PODD | Insulet Corporation | $301.00 | $175.12 | +71.9% | 2 | Nov 5, 2025 |
| ALC | Alcon Inc. | $86.00 | $74.45 | +15.5% | 1 | Oct 13, 2025 |
| HUMA | Humacyte, Inc. | $3.50 | $0.85 | +311.8% | 1 | Aug 27, 2025 |
| INMD | InMode Ltd. | $27.00 | $14.39 | +87.6% | 1 | Oct 12, 2024 |
| EW | Edwards Lifesciences Corporation | $80.00 | $84.24 | -5.0% | 2 | Sep 9, 2024 |
| DXCM | DexCom, Inc. | $113.00 | $61.51 | +83.7% | 1 | Jul 29, 2024 |
| ATEC | Alphatec Holdings, Inc. | $19.00 | $10.43 | +82.2% | 1 | Jul 8, 2024 |
| ABT | Abbott Laboratories | $140.00 | $89.76 | +56.0% | 1 | Apr 22, 2024 |
| ISRG | Intuitive Surgical, Inc. | $314.00 | $459.71 | -31.7% | 1 | Apr 19, 2023 |
| BSX | Boston Scientific Corporation | $54.00 | $56.91 | -5.1% | 1 | Sep 23, 2021 |
| SYK | Stryker Corporation | $311.00 | $297.71 | +4.5% | 1 | Jul 28, 2021 |
Recent Activity
- Apr 15, 2026— Set$255.00price target onJNJ(Johnson & Johnson)
- Feb 23, 2026— Set$56.00price target onTNDM(Tandem Diabetes Care, Inc.)
- Feb 18, 2026— Set$118.00price target onMDT(Medtronic plc)
- Feb 12, 2026— Set$100.00price target onZBH(Zimmer Biomet Holdings, Inc.)
- Feb 10, 2026— Set$202.00price target onBDX(Becton, Dickinson and Company)
- Jan 9, 2026— Set$30.00price target onBAX(Baxter International Inc.)
- Jan 8, 2026— Set$116.00price target onMDT(Medtronic plc)
- Dec 30, 2025— Set$217.00price target onJNJ(Johnson & Johnson)
- Dec 8, 2025— Set$91.00price target onCOO(The Cooper Companies, Inc.)
- Nov 5, 2025— Set$301.00price target onPODD(Insulet Corporation)
- Oct 13, 2025— Set$85.00price target onCOO(The Cooper Companies, Inc.)
- Oct 13, 2025— Set$86.00price target onALC(Alcon Inc.)
- Aug 27, 2025— Set$3.50price target onHUMA(Humacyte, Inc.)
- Oct 12, 2024— Set$27.00price target onINMD(InMode Ltd.)
- Sep 9, 2024— Set$80.00price target onEW(Edwards Lifesciences Corporation)
- Aug 5, 2024— Set$58.00price target onTNDM(Tandem Diabetes Care, Inc.)
- Jul 29, 2024— Set$113.00price target onDXCM(DexCom, Inc.)
- Jul 8, 2024— Set$19.00price target onATEC(Alphatec Holdings, Inc.)
- May 13, 2024— Set$200.00price target onPODD(Insulet Corporation)
- May 6, 2024— Set$245.28price target onBDX(Becton, Dickinson and Company)
Frequently Asked Questions
Who is Matt Miksic?
Matt Miksic is a stock analyst at Barclays covering 18 stocks primarily in Healthcare. They have issued 27 price targets since Jul 28, 2021.
What stocks does Matt Miksic cover?
Matt Miksic currently covers 18 stocks, including JNJ, TNDM, MDT, BDX, BAX.
What is Matt Miksic's latest price target?
Matt Miksic's most recent price target was $255.00 on JNJ (Johnson & Johnson), set on Apr 15, 2026.
What is Matt Miksic's highest price target?
Matt Miksic's highest issued price target is $314.00 on ISRG, set on Apr 19, 2023.
More Analysts at Barclays
Coverage based on publicly published price targets. Not investment advice.